BAYER CROPSCIENCE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,467 INR | +0.60% |
|
-1.84% | -1.19% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 29.61 and 26.92 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.33 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Agricultural Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -1.19% | 2.98B | C+ | ||
| +15.82% | 38.38B | C | ||
| -.--% | 11.15B | - | B+ | |
| -4.50% | 7.3B | A | ||
| +6.36% | 6.87B | B- | ||
| -3.91% | 5.91B | B+ | ||
| -10.40% | 5.6B | - | C- | |
| -4.54% | 5.54B | B | ||
| +33.14% | 5.19B | B- | ||
| -13.05% | 4.58B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
- Stock Market
- Equities
- BAYERCROP Stock
- Ratings Bayer CropScience Limited
